Sheep anti-Pseudomonas immunoglobulin and Pseudomonas vaccine were used for combined immunotherapy in 55 severely burned patients. The results of clinical investigations show that active and passive immunization in the early state of thermal injury increases the anti-Pseudomonas agglutinin titer, diminish the threat of Pseudomonas sepsis and death and significantly accelerate the recovery.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Systems serology in cystic fibrosis: Anti-Pseudomonas IgG1 responses and reduced lung function.
Cell Rep Med
October 2023
Center for Translational Research in Infection and Inflammation, School of Medicine, Tulane University, New Orleans, LA, USA. Electronic address:
Nearly one-half of patients with cystic fibrosis (CF) carry the homozygous F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene but exhibit variable lung function phenotypes. How adaptive immunity influences their lung function remains unclear, particularly the serological antibody responses to antigens from mucoid Pseudomonas in sera from patients with CF with varying lung function. Sera from patients with CF with reduced lung function show higher anti-outer membrane protein I (OprI) immunoglobulin G1 (IgG1) titers and greater antibody-mediated complement deposition.
View Article and Find Full Text PDFDevelopment of an anti- therapeutic monoclonal antibody WVDC-5244.
Front Cell Infect Microbiol
May 2023
Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, United States.
The rise of antimicrobial-resistant bacterial infections is a crucial health concern in the 21st century. In particular, antibiotic-resistant causes difficult-to-treat infections associated with high morbidity and mortality. Unfortunately, the number of effective therapeutic interventions against antimicrobial-resistant infections continues to decline.
View Article and Find Full Text PDFHumanization of the Shark V Single Domain Antibody Using CDR Grafting.
Curr Protoc
January 2023
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
The variable domain of the new antigen receptor (V ) of shark single domain antibodies is evolutionarily distant from the variable regions (V ) of mammalian immunoglobulins, yet it still has complementarity-determining regions (CDRs) that are involved in antigen recognition, therefore making it possible to humanize by grafting these CDRs to the framework of human V homologs. Here, we show the V CDR based on an analysis of currently available V -antigen structure complexes in the global Protein Data Bank archive of 3D structure data, and describe the detailed protocol to humanize V by CDR grafting, using B6 (an anti-Pseudomonas exotoxin V ), the most common type (Type II) of shark V s, as an example. Ongoing efforts will further optimize the protocol for moving shark V s to the clinic for treating cancer and other human diseases.
View Article and Find Full Text PDFSafety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial.
Crit Care
November 2022
Clinical Research and Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca Biopharmaceuticals, One MedImmune Way, Gaithersburg, MD, 20878, USA.
Article Synopsis
- Ventilator-associated pneumonia from Pseudomonas aeruginosa in hospitalized patients leads to high mortality, prompting the testing of the bispecific monoclonal antibody MEDI3902 (gremubamab) to prevent this condition in patients who are colonized with the bacteria.
- The EVADE study (NCT02696902) was a double-blind, placebo-controlled trial that recruited mechanically ventilated adults colonized with Pseudomonas aeruginosa and randomized them to receive either MEDI3902 or a placebo, focusing on the incidence of pneumonia over 21 days post-treatment.
- Results showed no significant difference in the incidence of pneumonia between the MEDI3902 and placebo groups, with 22.4
Understanding -Host Interactions: The Ongoing Quest for an Efficacious Vaccine.
Cells
December 2020
School of Biomolecular and Biomedical Sciences, University College Dublin, Belfield, Dublin 4, D04 V1W8, Ireland.
is a leading cause of chronic respiratory infections in people with cystic fibrosis (CF), bronchiectasis or chronic obstructive pulmonary disease (COPD), and acute infections in immunocompromised individuals. The adaptability of this opportunistic pathogen has hampered the development of antimicrobial therapies, and consequently, it remains a major threat to public health. Due to its antimicrobial resistance, vaccines represent an alternative strategy to tackle the pathogen, yet despite over 50 years of research on anti- vaccines, no vaccine has been licensed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!